Welcome to our dedicated page for Capricor Therapeutics news (Ticker: CAPR), a resource for investors and traders seeking the latest updates and insights on Capricor Therapeutics stock.
Capricor Therapeutics Inc (NASDAQ: CAPR) generates news primarily around its development of cell and exosome-based therapeutics for rare diseases, with a strong focus on Duchenne muscular dystrophy (DMD). The company’s announcements frequently highlight clinical trial milestones for its lead investigational therapy, Deramiocel (CAP-1002), as well as updates on its StealthX™ exosome platform.
Investors and followers of CAPR news can expect detailed coverage of clinical trial results and regulatory interactions. Recent communications include positive topline results from the pivotal Phase 3 HOPE-3 study of Deramiocel in DMD, information on primary and secondary endpoints such as Performance of Upper Limb (PUL v2.0) and left ventricular ejection fraction, and commentary from clinical investigators. Capricor also reports on its engagement with the U.S. Food and Drug Administration, including a Complete Response Letter for its Biologics License Application and subsequent Type A meeting to align on the role of HOPE-3 data in the regulatory pathway.
News items also cover corporate and financial developments, such as quarterly financial results, public offerings of common stock, and manufacturing readiness at the company’s GMP facility in San Diego, California. In addition, Capricor issues updates on scientific publications and conference presentations, including peer-reviewed work describing Deramiocel’s mechanism of action and data on scalable loading of therapeutic oligonucleotides into exosomes.
For those tracking CAPR, this news feed provides a centralized view of clinical, regulatory, scientific and financing updates directly related to Capricor’s programs. Regular review of these items can help readers follow the progress of Deramiocel in DMD, developments in the StealthX™ platform, and key corporate decisions that shape the company’s therapeutic pipeline.
Capricor Therapeutics (NASDAQ: CAPR) has initiated the pivotal Phase 3 HOPE-3 clinical trial for CAP-1002, targeting patients with late-stage Duchenne Muscular Dystrophy (DMD). Positive results from the HOPE-2 open label extension study showcase significant improvements in muscle function. The company is pursuing FDA discussions for CAP-1002's development. Financially, Capricor reported a net loss of $7.1 million for Q2 2022, but has sufficient cash to fund operations into Q2 2024. A partnership with Nippon Shinyaku supports HOPE-3 with a $30 million upfront payment.
Capricor Therapeutics (NASDAQ: CAPR) announces it will release its financial results for the second quarter ended June 30, 2022, after market close on August 10, 2022. A conference call will be held at 4:30 p.m. ET the same day to discuss the results and provide a corporate update. Capricor focuses on developing cell and exosome-based therapeutics, particularly its lead candidate, CAP-1002, for treating Duchenne muscular dystrophy. More details can be found at capricor.com.
Capricor Therapeutics (NASDAQ: CAPR) has announced the start of patient dosing in the HOPE-3 Phase 3 clinical trial for CAP-1002, a cell therapy aimed at treating late-stage Duchenne muscular dystrophy (DMD). This randomized, double-blind, placebo-controlled study is set to enroll about 70 patients in the U.S. Positive results from the earlier HOPE-2 trial suggested CAP-1002 could slow the loss of upper limb function by up to 70%. A partnership with Nippon Shinyaku Co., Ltd. will support this trial's funding, while CAP-1002 holds regulatory designations that may facilitate its path to market approval.
Capricor Therapeutics (NASDAQ: CAPR) announces positive one-year results from its HOPE-2 open label extension study for CAP-1002 in non-ambulant patients with Duchenne muscular dystrophy (DMD). The study met its primary endpoint, showing significant improvements in the Performance of the Upper Limb (PUL 2.0) scale (p=0.02). CAP-1002 was administered to 20 original patients, 12 of whom completed the year-long follow-up. The FDA has granted CAP-1002 RMAT and Orphan Drug Designation. Capricor plans to present these findings to the FDA while currently conducting a Phase 3 trial (HOPE-3).
Capricor Therapeutics (NASDAQ: CAPR) announced it will present one-year results from its HOPE-2 study on June 25, 2022, at the PPMD Annual Conference in Scottsdale, Arizona. Dr. Linda Marbán will lead a late-breaking session at 5:05 p.m. MT, sharing safety and efficacy results for their lead asset CAP-1002, aimed at treating Duchenne muscular dystrophy (DMD). The conference, the largest international event for DMD research, will occur from June 22-26, 2022, with an option for virtual attendance.
Capricor Therapeutics has appointed Xavier Avat as Chief Business Officer to enhance its commercial strategy for CAP-1002, which targets Duchenne muscular dystrophy. With over 25 years of experience at leading biotech firms, Avat will oversee the commercialization of Capricor's products and business development initiatives. CEO Linda Marbán emphasized Avat's potential to drive growth and strengthen the company's positioning in rare diseases. Capricor is also expanding its proprietary exosome technology as part of its therapeutic portfolio.
Capricor Therapeutics (NASDAQ: CAPR) announced that CEO Dr. Linda Marbán will present at the H.C. Wainwright Global Investment Conference from May 23-26, 2022, in Miami, Florida. The presentation is scheduled for May 25, 2022, at 9:30 a.m. ET. Investors can register for the event through a provided link. Capricor, focused on developing transformative cell and exosome-based therapeutics, is advancing its lead candidate, CAP-1002, for Duchenne muscular dystrophy. The company aims to create exosomes for delivering nucleic acids to treat various diseases.
Capricor Therapeutics (NASDAQ: CAPR) announced a partnership with Nippon Shinyaku for the commercialization of CAP-1002 for Duchenne muscular dystrophy (DMD). The collaboration includes an upfront payment of $30 million and potential milestone payments up to $705 million. Positive Phase 2 results published in The Lancet confirm CAP-1002's efficacy in improving muscle function. The Phase 3 HOPE-3 trial is set to start this quarter, with about 70 patients expected to enroll across multiple sites. As of March 31, 2022, Capricor reported a net loss of $7.8 million, while cash reserves increased to $58.3 million.
Capricor Therapeutics (NASDAQ: CAPR) will announce its first quarter 2022 financial results on May 10, 2022, followed by a conference call at 4:30 p.m. ET. The company focuses on developing cell and exosome-based therapeutics for various diseases, with its lead candidate, CAP-1002, aimed at treating Duchenne muscular dystrophy. The call will discuss recent corporate updates and financial performance. A replay will be available post-broadcast. Investors can access the call via a toll-free number or a webcast link.
Capricor Therapeutics (NASDAQ: CAPR) announced that CEO Dr. Linda Marbán will participate in a panel discussion at the Cantor Fitzgerald Rare Orphan Disease Summit on March 30, 2022, at 4:00 p.m. ET. The panel will focus on cell therapy and its expanding definitions and applications for rare diseases. Capricor is a biotechnology company dedicated to developing cell and exosome-based therapeutics to address various diseases, including Duchenne muscular dystrophy and COVID-19 cytokine storms.
FAQ
What is the current stock price of Capricor Therapeutics (CAPR)?
What is the market cap of Capricor Therapeutics (CAPR)?
